U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07108140) titled 'Engineered T-cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors' on July 21.
Brief Summary: This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of ALPP CAR-T cells in patients with ALPP-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in solid tumors.
Study Start Date: May 20
Study Type: INTERVENTIONAL
Condition:
Solid Tumor
Intervention:
BIOLOGICAL: Anti A...